Biotech Adam Feuerstein and Damian Garde A turnaround for Editas Medicine, a CRISPR laggard, hinges on updates on key treatments
Biotech Megan Molteni A new suite of RNA-sensing tools could help scientists target cancerous cells, and much more
Biotech Allison DeAngelis New CRISPR startup, drawing big-name backers, seeks to fix diseases caused by large DNA errors
In the Lab Megan Molteni CRISPR debuted 10 years ago, in a paper hardly anyone noticed. Jennifer Doudna reflects on the DNA scissors’ first decade
In the Lab Sharon Begley You had questions for David Liu about CRISPR, prime editing, and advice to young scientists. He has answers
Biotech Megan Molteni PACT Pharma’s personalized cancer treatments, powered by CRISPR, clear early safety hurdles
Biotech Ryan Cross — The Boston Globe Muscular dystrophy patient who was first in line for a custom CRISPR therapy dies
The Readout LOUD Damian Garde, Allison DeAngelis and Adam Feuerstein Listen: Biden’s Covid declaration, twilight of the SPAC, & genome editing 2.0
Pharmalot Ed Silverman Pharmalittle: CRISPR-based drug shows promise in preliminary study; FDA user fee program prompts fresh worries over conflicts
Biotech Megan Molteni Intellia says CRISPR treatment safely corrects DNA of six patients with rare disease
The Readout LOUD Damian Garde and Adam Feuerstein Listen: CRISPR for the heart, biotech’s recovery, & what it means to be a ‘hot girl’
Biotech Jason Mast Beyond a CRISPR treatment’s encouraging results, some scientists see a need for more data on risk
Biotech Adam Feuerstein Updated study results show a CRISPR treatment for blood diseases continues to benefit patients
Biotech Adam Feuerstein A Caribou CAR-T treatment, backed by Nobel-winning science, shows blood-cancer remissions in first data reveal
First Opinion Walter G. Johnson and Diana M. Bowman It’s time for Congress to stop blocking mitochondrial replacement therapy
Biotech Megan Molteni In the wake of big patent decision, it’s business as usual for CRISPR therapy developers
Exclusive Megan Molteni New details emerge about a U.S. scientist’s obscured role in the ‘CRISPR babies’ scandal
The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein Listen: Biden’s plans for Covid pills, the latest vaccine data, & fighting about CRISPR
Biotech Megan Molteni UC Berkeley loses CRISPR patent case, invalidating patent rights it granted gene-editing companies developing human therapies
Biotech Adam Feuerstein Intellia Therapeutics shows improved, sustained effect from in vivo CRISPR treatment
Biotech Megan Molteni With new trial data coming, Intellia CEO talks up the future of in vivo gene editing
The Readout LOUD Damian Garde and Meg Tirrell Jennifer Doudna and Marty Chavez on where CRISPR meets Wall Street
The Readout LOUD Damian Garde, Meg Tirrell and Adam Feuerstein Listen: Robert Califf’s FDA return, the future of CRISPR, & another vaccine delay
In the Lab Megan Molteni Drugs based on next-generation gene editing are moving toward the clinic faster than CRISPR 1.0